The success of antiretroviral therapy for HIV/AIDS “has fooled us into believing HIV is under control. It is not. â€¦ The fact remains that no sexually acquired infection has ever been controlled in democratic societies except by vaccines,” Lawrence Corey, president and director of the Fred Hutchinson Cancer Research Center and principal investigator of the international HIV Vaccine Trials Network, writes in a Wall Street Journal opinion piece.
“A vaccine to prevent cervical cancer, triggered by the human papillomavirus (HPV), has helped reduce the number of teenage girls developing abnormalities in their cervix by as much as 50 percent in a study in Australia,” according to a report published Friday in the Lancet, Reuters reports.
The Economist examines how “the past decade has seen changes in how vaccines are developed, financed and delivered â€“ solving, at least partially, the conundrum of the vaccine market: poor regions have ample demand for vaccines but little ability to pay for them. As a result, immunisation rates in the poor world have soared.”
Commenting on the U.S. pledge of $450 million to the GAVI Alliance, Gayle Smith, special assistant to the President and senior director for Development and Democracy for the National Security Staff, writes in a White House Blog post, “Investments in vaccines are one of the best and most cost-effective life-saving…
“I can’t help worrying that, as donors slap themselves on the back over their generosity [shown through pledges to the GAVI Alliance] â€¦, their feelgood factor will turn into a warm glow of satisfaction at having played out their part. Problem solved,” Sarah Boseley writesÂ on the Guardian’sÂ “Global Health Blog.” “What…
The meningococcal vaccine MenAfriVac, which is made by the Indian generic drug company Serum Institute, is “dramatically better” at producing a protective effect among African children in three countries than “older so-called meningococcal polysaccaride vaccines, including Mencevax from GlaxoSmithKline,” according to a paper describing two studies published in the New England Journal of Medicine, Reuters reports.
Editorials and opinion pieces are responding to the GAVI Alliance pledging conference, which raised $4.3 billion for childhood vaccinations. The following is a summary of some of those pieces: Financial Times: Boosting vaccines: The editorial calls on GAVI to review its governance and do more to help reduce the price…
“Large donations from the U.K., Norway and the Bill & Melinda Gates Foundation helped a global vaccine charity raise $4.3 billion at a summit Monday, exceeding its targets and allowing it to carry out all its immunization plans through 2015,” the Wall Street Journal reports. The U.K. pledged $1.34 billion to the GAVI Alliance, the Gates Foundation promised $1 billion and Norway offered $677 million (Whalen, 6/14).
The New York Times reports on the success of a new meningococcal vaccine in West Africa, where very few cases of the disease have been detected in countries that use MenAfriVac, which costs 50 cents per dose.
A vaccine against the mosquito-borne infection dengue, the first to reach the final stage of clinical testing, “has seen ‘very promising’ results in Thailand, a specialist involved in the tests said on Friday,” Reuters reports (Petty/Mahlich, 6/10).